Emerging therapeutic strategies for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) increasingly center on incretin-based agents, particularly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, such as tirzepatide, and GLP-1/glucagon receptor co-agonists like survodutide. This evidence concerns the gene GIP and liver disorder.